I’m not an intellectual property lawyer. Seemingly neither are you. However one of us said that the issue was suspension in fluid. To help you recall that, that was what you insisted is the reason Pfizer didn’t proceed and the key to the IP moat.
I asked you for a source and you tell me that I should be able to work it out. I can’t honestly work it out but you seemingly know and won’t point me to a source. You and the other chap have snipped parts of the Prospectus for me but they don’t explain the issue for me.
I’ve used what limited skills I have to come to a view that I expressed. You’ve now told me I’m the expert and I should work it out.
I can’t get to an answer that allays concerns. You’ve told me my concerns are not cogent, that it’s “vibe”, that my view is irrational and now to understand why I’m the expert and I can work it out.
So for the last time, what is the source re the Pfizer project and crystallisation? Is there evidence that LTP has addressed the areas of concern, and if so, what are the further studies considering specifically. With those specific issues in mind what is the scale and cost of the trials. Finally, what is the terminal value of the IP where LTP seems to be commercialising something without a long term exclusivity.
those questions determine if this is gambling or not.
Add to My Watchlist
What is My Watchlist?
